DEFA14A: Dynavax Responds to Deep Track's Board Nomination, Highlights Value Creation Strategy

Dynavax addresses Deep Track Capital's nomination of board candidates, emphasizing its strong financial performance and commitment to long-term stockholder value.

Summary

• Dynavax has issued a statement in response to Deep Track Capital's nomination of four candidates for election to the company's Board of Directors at the 2025 Annual Meeting of Stockholders.
• The company highlights its strong financial performance, driven by HEPLISAV-B growth, advancement of its vaccine pipeline, and disciplined capital allocation.
• HEPLISAV-B achieved record annual revenue in 2024, with 26% year-over-year growth, and the company expects to reach at least 60% total market share by 2030.
• Dynavax is advancing a novel shingles vaccine program and has secured a $30 million contract with the U.S. Department of Defense for its plague vaccine program.
• The company's balance sheet shows $714 million in cash as of year-end 2024, supporting pipeline development and strategic acquisitions.
• Dynavax initiated a $200 million share repurchase plan in November 2024, with $100 million executed through an accelerated program.
• The company discontinued its Tdap program in the third quarter of 2024 due to unsatisfactory study results.
• The Board of Directors has initiated a refreshment program, appointing two new independent directors and planning for two current directors to step down at the 2025 Annual Meeting.
• The Board intends to seek stockholder approval for the declassification of the Board at the 2025 Annual Meeting.
• Dynavax has engaged with Deep Track for many years but disagrees with their proposed strategy of abandoning portfolio diversification and implementing an outsized share repurchase program.
• The Board has made multiple settlement offers to Deep Track, including board appointments, but Deep Track has insisted on gaining control of the Board by 2026 without paying a control premium.
• Dynavax remains committed to constructive engagement with Deep Track while protecting the interests of all stockholders.
• The Board will review Deep Track's materials and present its formal recommendation regarding director nominations in its proxy statement.

Sentiment

Score: 7

Explanation: The document conveys a generally positive sentiment, highlighting strong financial performance and strategic initiatives. However, the ongoing proxy contest with Deep Track Capital introduces uncertainty and potential risks, slightly tempering the overall positive outlook.

Positives

• Strong HEPLISAV-B revenue growth of 26% year-over-year in 2024.
• Healthy cash balance of $714 million at the end of 2024.
• Share repurchase program to return capital to stockholders.
• Advancement of a differentiated vaccine pipeline, including a novel shingles vaccine program.
• New $30 million contract with the U.S. Department of Defense.
• Board refreshment with the appointment of two new independent directors.
• Intention to declassify the Board, potentially improving corporate governance.

Negatives

• Deep Track Capital is pushing for a strategy that Dynavax believes is value-destructive.
• Deep Track is seeking control of the Board without paying a control premium.
• The Tdap program was discontinued due to unsatisfactory study results.
• A potential proxy contest with Deep Track could be distracting and costly.

Risks

• The proxy contest with Deep Track could divert management's attention and resources.
• Failure to achieve the expected 60% market share for HEPLISAV-B by 2030.
• Risks associated with commercializing and supplying HEPLISAV-B.
• Uncertainties related to the implementation of long-term growth objectives.
• The risk that circumstances surrounding or leading up to the 2025 Annual Meeting may change.

Future Outlook

Dynavax expects to achieve at least 60% total market share for HEPLISAV-B by 2030 and is focused on advancing its vaccine pipeline and pursuing strategic acquisitions.

Management Comments

• Dynavax has been successfully executing a clear strategic plan focused on three core priorities which is consistently delivering strong financial results and sustainable long-term value.
• Deep Tracks strip-mining plan for Dynavax jeopardizes a strong platform with significant long-term growth opportunities for a near-term payoff of a considerably lower value.
• Dynavax remains committed to constructive and reasonable engagement with Deep Track, while ensuring that the best interests of all stockholders are protected and represented.

Industry Context

The shingles vaccine market is a multi-billion dollar global market, and Dynavax is aiming to disrupt it with its novel vaccine program. The company's HEPLISAV-B competes with other hepatitis B vaccines, and its growth reflects its competitive position in the market.

Comparison to Industry Standards

• Dynavax's HEPLISAV-B is competing with established hepatitis B vaccines from companies like GlaxoSmithKline and Merck.
• The company's shingles vaccine program aims to compete with Shingrix, a highly successful vaccine from GlaxoSmithKline.
• The $30 million contract with the U.S. Department of Defense for the plague vaccine program is comparable to other government contracts awarded to pharmaceutical companies for vaccine development.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company aims to deliver long-term value through its strategic plan and capital allocation.
• Employees: The company's growth and pipeline development may create opportunities for employees.
• Customers: HEPLISAV-B provides protection against hepatitis B infection.
• U.S. Department of Defense: The $30 million contract supports the development of a plague vaccine.

Next Steps

• The Board will review Deep Track's materials and present its formal recommendation regarding director nominations in its proxy statement.
• Stockholders will vote on director nominations and a proposal to declassify the Board at the 2025 Annual Meeting.
• The company will continue to execute its strategic plan, focusing on HEPLISAV-B growth, pipeline development, and disciplined capital allocation.

Key Dates

Keywords

Dynavax, HEPLISAV-B, Deep Track Capital, Board of Directors, Vaccine, Share Repurchase, Proxy Contest, Capital Allocation, Governance, Stockholders